Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, reported encouraging interim results from its Phase 2a clinical trial of HT-001, an investigational topical treatment for skin toxicities induced by Epidermal Growth Factor Receptor Inhibitors or EGFRi in cancer patients.
The Phase 2a trial, dubbed CLEER-001, consists of two parts - Part 1 and Part 2.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.